   
CORE VALUES 
© Quality Cc 
e Trustworthiness ~) | 
©} commitment Aptus Pharma Limited 
(8) Harawork Connecting...... Life 
www.aptus-pharma.com | info@aptuspharma.com | export@aptuspharma.com | +91 76004 27827 
NOV-21-2025 
  
2011 
  
The Deputy Manager 
Corporate Relationship Department 
BSE Limited 
P. J. Towers, Dalal Street, 
Mumbai ~ 400001 
Scrip Code: 544529 
ISIN: INE15XJ01010 
Dear Sir/Madam. 
Sub: Intimation pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 
regarding entry into the Urology therapy segment. 
  
Pursuant to Regulation 30 of the SEBI (Listing Obligations arid Disclosure Requirements) 
Regulations, 2015, we are enclosing herewith a press release issued by “the Company” on 
the above captioned subject. 
Contents of the press release are self-explanatory, 
You are requesied to take the above cited information on your records. 
Thanking you, 
Yours faithfully 
For Aptus Pharma Limited 
~/ ~ " , ¢ 
a 
Tejash Maheshchandra Hathi 
Managing Director 
DIN: 03151221 
  
CIN : U24230GJ2010PLC061957 | GSTIN NO. 24AAICA7890D1ZM aptuspharmaltd. y) (f) 
Registered Office : Ashutosh Buildcon, Opp. Slok-2, Nr. Harikrupa logistic Park, | Corporate Office : SHREE Building, 1st Floor, Opp Satyasai Heart Hospital, 
Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427 Narayan Nagar, Kalawad Road, Sau Uni Area, Rajkot, Gujarat, India, 360005
CORE VALUES 
© Quality : ©) 
e Trustworthiness ~) 
ge Serine Aptus Pharma Limited 
€} Harawork Connecting...... Life 
www.aptus-pharma.com | info@aptuspharma.com | export@aptuspharma.com | +91 76004 27827 
mz 
RJ 
oS —_ 
— 
    
PRESS RELEASE 
Aptus Pharma Limited has announced its strategic entry into the Urology therapy segment as part 
of its ongoing business expansion initiatives. 
The Company will soon be launching a new portfolio of products in this segment, including: 
e Silodosin range 
e Tamsulosin range 
e Alkalizer formulations 
The introduction of these products is supported by the Company’s strong field-sales force and a robust 
distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new 
portfolio is expected to contribute significantly to the Company’s future revenue growth and 
profitability. 
The Indian urology market is one of the fastest-growing chronic therapy segments, currently 
expanding at approximately 9-10% annually. 
Commenting on this development, Tejash Hathi, Managing Director, Aptus Pharma Limited., 
stated: 
“Our entry into the urology therapy segment further strengthens our specialty-care capabilities and 
positions the Company for sustained growth in the coming years.” 
About Aptus Pharma Limited 
Aptus Pharma Limited is a growing pharmaceutical company engaged in multiple therapeutic areas, 
supported by an extensive distribution network and a dedicated sales force. The Company continues 
to expand its presence in specialty and chronic therapy segments as part of its jong-term strategic 
roadmap. 
APTUS PHARMA LTD. 
} mom 
AF atlhgna sere 
  
D1zM CIN : U24230GJ2010PLC061957 | GSTIN NO. 24AAICA7890 aptuspharmaltd. OHO 
Registered Office : Ashutosh Buildcon, Opp. Slok-2, Nr. Harikrupa logistic Park, 
Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427 
Corporate Office : SHREE Building, 1st Floor, Opp Satyasai Heart Hospital, 
Narayan Nagar, Kalawad Road, Sau Uni Area, Rajkot, Gujarat, India, 360005  
